Acute myeloblastic leukemia. Acute myeloblastic leukemia
Conditions
Interventions
Intervention 1: Intervention group: receive the standard treatment Cytarabine and idarubicin (7+3) with oral intake of Deferasirox capsule 360 mg daily for 28 days. Intervention 2: Control group: rece
Sponsors
Kerman University of Medical Sciences
Nano Fanavaran Alvand pharmaceutical co.
AryaTinaGene biopharmaceutical co.
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Age between 18-65 years AML/non-APL
Exclusion criteria
Exclusion criteria: HIV infected patients or Hepatitis B,C patients Patients with AML-induced neurological involvement Patients with uncontrolled blood pressure and heart failure Patients with a history of ocular toxicity due to iron chelators drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of white blood cells. Timepoint: on days 14 and 28. Method of measurement: Test for complete blood cell count.;Number of red blood cells. Timepoint: on days 14 and 28. Method of measurement: Test for complete blood cell count.;Platelet numbers. Timepoint: on days 14 and 28. Method of measurement: Test for complete blood cell count.;Percentage of CD34 + leukemia blasts of bone marrow biopsy specimen. Timepoint: on days 14 and 28. Method of measurement: Flow cytometry with CD34 monoclonal antibody. | — |
Secondary
| Measure | Time frame |
|---|---|
| Reactive oxygen species rate in +CD34 leukemic blasts bone marrow biopsy sample. Timepoint: on days 14 and 28. Method of measurement: Flow cytometry.;The rate of apoptotic cells in +CD34 leukemic blasts bone marrow biopsy sample. Timepoint: on days 14 and 28. Method of measurement: Flow cytometry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAliasghar Tirgar
Kerman University of Medical Sciences
Outcome results
None listed